Psoriatic Arthritis News and Research

RSS
Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.
National Psoriasis Foundation introduces patient-centered research network

National Psoriasis Foundation introduces patient-centered research network

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

LEO Pharma reports encouraging data from PSO-FAST clinical trial of Enstilar for psoriasis treatment

LEO Pharma reports encouraging data from PSO-FAST clinical trial of Enstilar for psoriasis treatment

National Psoriasis Foundation awards grants to support psoriatic disease research

National Psoriasis Foundation awards grants to support psoriatic disease research

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

National Psoriasis Foundation’s online research community receives second-year of funding from PCORI

National Psoriasis Foundation’s online research community receives second-year of funding from PCORI

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

MorphoSys to receive milestone payment for guselkumab program in psoriatic arthritis

MorphoSys to receive milestone payment for guselkumab program in psoriatic arthritis

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Psoriasis management: an interview with Dr Sandy McBride

Psoriasis management: an interview with Dr Sandy McBride

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Researchers identify genetic variants associated with psoriatic arthritis

Researchers identify genetic variants associated with psoriatic arthritis

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Scientists take a huge step forward in identifying root causes of psoriasis

Scientists take a huge step forward in identifying root causes of psoriasis